RxDoctor Payments Data

Brett Foersterling, MD

Family Medicine · Saint Louis, MONPI 1669421590

Payments from drug & device makers

$1,102in general payments, 2019–2025

Across 65 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$421
  • AbbVie$288
  • GSK$195
  • Dexcom, Inc.$66
  • Astellas Pharma US Inc$45
  • Novartis$17
  • plus $70 from 5 others

What the payments were for

  • Food & beverage$1,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer21$421
AbbVie(2 entities)18$288
GSK13$195
Dexcom, Inc.4$66
Astellas Pharma US Inc3$45
Novartis1$17
Amgen1$17
Daiichi Sankyo Inc.1$16
Novo Nordisk1$14
Abbott1$12
Insulet Corporation1$12

How this compares

$1,102 in reported general payments places this provider in the 65th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$33,729
Medicare patients
93
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$91,312
EliquisApixaban62$45,378
MounjaroTirzepatide19$22,873
JardianceEmpagliflozin19$20,372
XareltoRivaroxaban23$14,614
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$11,601
Spiriva RespimatTiotropium Bromide15$7,710
Atorvastatin Calcium565$7,650
Dabigatran EtexilateDabigatran Etexilate Mesylate12$6,435
TrintellixVortioxetine Hydrobromide12$5,681
ArexvyRsvpref3 Antigen/As01e/Pf21$5,514
Insulin Aspart FlexpenInsulin Aspart16$4,309
Metoprolol Succinate232$3,935
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,581
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$91,31285 claims
PfizerEliquis$421$45,37862 claims
GSKArexvy$195$5,51421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →